higher risk of progression to end-stage renal disease (ESRD) who accept a potential increased risk of infection. This recommendation is supported by data from the 2 largest trials of plasma exchange for the treatment of glomerulonephritis in AAV. The first trial, which required a serum creatinine level of â‰¥5.8 mg/ dl for entry, showed that plasma exchange decreased the risk of ESRD but did not decrease mortality However, combined data from these 2 trials show that there is probably a decreased